TREMFYA® results are starting to be
reaffirmed in the real world,3-5 to
benefit your patients day-to-day.



1-year retrospective
longitudinal study		  

52 patients with
moderate-to-severe
chronic plaque psoriasis
(PASI >10) who had failed
to respond to, or had
contraindications or side
effectst to, at least one
conventional treatment,
including systemic
therapy or phototherapy		  

TREMFYA administrated
SC at weeks 0 and 4
(induction phase)
and every 8 weeks
thereafter (maintenance)
for more or less
than 12 weeks		  

TREMFYA was observed
to be generally well
tolerated and effective
in this real-world setting,
including in
difficult-to-treat areas
 
Clinical efficacy for real patients.1

 
 


 
 
 
REFERENCES SEE MORE OF THE LATEST DATA
ON THE JANSSEN MEDICAL CLOUD™		 PRESCRIBING
INFORMATION

 
TREMFYA® is indicated for adults with moderate-to-severe plaque
psoriasis (Pso) who are candidates for systemic therapy.10

Tremfya®, alone or in combination with methotrexate (MTX), is indicated
for the treatment of active psoriatic arthritis in adult patients who have
had an inadequate response or who have been intolerant to a prior
disease-modifying antirheumatic drug (DMARD) therapy. 10

Please ensure you review your local Prescribing Information and/or
Summary of Product Characteristics and directly consult
your local Janssen affiliate to address questions.		 Privacy notice  Legal notice

This is published by Janssen Pharmaceutica NV which is solely responsible
for its content. It is intended for EMEA Healthcare professionals.
Third party trademarks used herein are trademarks of their respective owners.
Date of preparation: March 2021.  CP-214600